A Randomised Phase II trial investigating the duration of adjuvant therapy(6 versus 12 months) with S-1 for patients after resection of pancreatic cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PACS1
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2016 Planned number of patients changed from 240 to 170, as reported by University Hospital Medical Information Network - Japan.
- 06 Jan 2014 New trial record